Dose of Confidence—Sanjivani Paranteral Turns Warrants into Equity Power

Image Source: Pharma Industrial India

Sanjivani Paranteral Ltd., a research-based pharmaceutical firm, has okayed the conversion of 125,212 convertible warrants to equity shares as per a regulatory filing with the Bombay Stock Exchange. This is part of the larger capital-raising effort through preferential allotment to promoters and select investors.

The warrants, initially issued at ₹135.10 per share, were subscribed by the promoters in late 2024. With this conversion, the company has issued fully paid-up equity shares that will have the same rank as the existing shares and will be listed for trading on the BSE.

Highlights

Warrant Conversion: 125,212 warrants were converted into equity shares of ₹10 each.
Issue Price: ₹135.10 per share (inclusive of premium).
Allotment Date: Shares alloted on November 25, 2024.
Listing Date: Shares listed and permitted for dealing from January 13, 2025.
Lock-in Period: Shares will remain lock-in till August 2, 2026, based on SEBI regulations.
Promoter Impact: The conversion brings promoter holding together and reflects long-term belief in the growth story of the company.

Strategic Context

This conversion is part of a larger preferential issue approved by shareholders in January 2024 to help the company issue a maximum of 600,000 warrants to promoter Mr. Ashwani Khemka. The funds raised have been used to upgrade plant facilities, step up R&D capabilities, and for a joint venture with Hindustan Antibiotics Ltd. for IV formulations.

The move also aligns with Sanjivani’s broader strategy to enhance shareholder value, improve liquidity, and support its export-driven growth model across 25 countries.

Sources: BSE Notice, Indian Startup News, Sanjivani Paranteral EGM Notice, Screener